HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Metabolomic Analysis of Platelets of Patients With Aspirin Non-Response.

Abstract
Background: Aspirin is the most commonly used antiplatelet agent for the prevention of cardiovascular diseases. However, a certain proportion of patients do not respond to aspirin therapy. The mechanisms of aspirin non-response remain unknown. The unique metabolomes in platelets of patients with coronary artery disease (CAD) with aspirin non-response may be one of the causes of aspirin resistance. Materials and Methods: We enrolled 29 patients with CAD who were aspirin non-responders, defined as a study subject who were taking aspirin with a platelet aggregation time less than 193 s by PFA-100, and 31 age- and sex-matched patients with CAD who were responders. All subjects had been taking 100 mg of aspirin per day for more than 1 month. Hydrophilic metabolites from the platelet samples were extracted and analyzed by nuclear magnetic resonance (NMR). Both 1D 1H and 2D J-resolved NMR spectra were obtained followed by spectral processing and multivariate statistical analysis, such as partial least squares discriminant analysis (PLS-DA). Results: Eleven metabolites were identified. The PLS-DA model could not distinguish aspirin non-responders from responders. Those with low serum glycine level had significantly shorter platelet aggregation time (mean, 175.0 s) compared with those with high serum glycine level (259.5 s). However, this association became non-significant after correction for multiple tests. Conclusions: The hydrophilic metabolic profile of platelets was not different between aspirin non-responders and responders. An association between lower glycine levels and higher platelet activity in patients younger than 65 years suggests an important role of glycine in the pathophysiology of aspirin non-response.
AuthorsJiun-Yang Chiang, Sheng-Han Lee, Yen-Ching Chen, Cho-Kai Wu, Jing-Yuan Chuang, Shyh-Chyi Lo, Huei-Ming Yeh, Shih-Fan Sherri Yeh, Cheng-An Hsu, Bin-Bin Lin, Pi-Chu Chang, Chih-Hsin Chang, Hao-Jan Liang, Fu-Tien Chiang, Ching-Yu Lin, Jyh-Ming Jimmy Juang
JournalFrontiers in pharmacology (Front Pharmacol) Vol. 10 Pg. 1107 ( 2019) ISSN: 1663-9812 [Print] Switzerland
PMID31680941 (Publication Type: Journal Article)
CopyrightCopyright © 2019 Chiang, Lee, Chen, Wu, Chuang, Lo, Yeh, Yeh, Hsu, Lin, Chang, Chang, Liang, Chiang, Lin and Juang.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: